CommercialCoverageMedium impact
08.01.35k, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
A commercial policy update for Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®) has been posted, affecting pharmacy coverage. This is a very recent update that may impact billing procedures for this specialized oncology medication used in leukemia treatment.
Action Required
By January 1, 2026: Review the full policy details at the provided URL to determine specific billing requirements for Rylaze® (Asparaginase Erwinia Chrysanthemi). Oncology billing staff should verify any prior authorization requirements, coverage criteria, or documentation needs for this medication. Update pharmacy billing protocols accordingly to ensure claims compliance.